在抗肺结核化疗期间,甲福明对全身化基因反应的影响
Nathella Pavan Kumar1, Chandrasekaran Padmapriyadarsini1, Arul Nancy2
1ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Tuberculosis (Edinburgh, Scotland)
|June 8, 2024
概括
作为抗结核治疗 (ATT) 的辅助疗法,甲胺 (MET) 可能会减少有害的炎症. 这项研究发现,MET在结核病患者中显著降低了特定的化学激素,这表明它有可能在治疗期间制过度炎症.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 甲胺 (MET) 由于其增强免疫力的特性,正在作为抗结核治疗 (ATT) 的辅助疗法进行研究.
- 结核病 (TB) 治疗可能与过度炎症有关,影响患者的治疗结果.
研究的目的:
- 为了研究添加甲福明到标准抗结核治疗对宿主化学激素反应的影响.
- 为了确定在治疗期间,甲福明是否会影响活跃结核病患者的血化学基因水平.
主要方法:
- 在接受标准ATT的活跃结核病患者上进行了一项临床研究.
- 在治疗前,治疗2个月后和治疗6个月后,在接受和不接受甲福林的患者中测量了血化学激素水平.
- 分析了包括CC和CXC类型在内的广泛的化学因子组.
主要成果:
- 在ATT的2个月和6个月后,添加甲胺导致CC化学因子 (CCL1,CCL3) 和CXC化学因子 (CXCL-2,CXCL-10) 的水平显著降低.
- 这些化学基因减少在高细菌负担和腔腔疾病的患者中更为明显.
- 与非甲胺组相比,甲胺改变了宿主化学激素特征.
结论:
- 在抗肺结核治疗期间,甲福明会改变化学因反应.
- 这些变化表明甲双可能在抑制结核病治疗相关的过度炎症方面发挥作用.
相关概念视频
Pulmonary Tuberculosis I
231
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
231
Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
157
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
157
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
261
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
261


